Anti-vascular endothelial growth factor for macular oedema secondary to branch retinal vein occlusion

Author:

Shalchi Zaid12,Mahroo Omar1,Bunce Catey3,Mitry Danny14

Affiliation:

1. Moorfields Eye Hospital NHS Foundation Trust; London UK

2. Royal Berkshire NHS Foundation Trust; Reading UK

3. London UK

4. Royal Free Hospital, NHS Foundation Trust; London UK

Publisher

Wiley

Subject

Pharmacology (medical)

Reference117 articles.

1. A 12-month, multicenter, parallel group comparison of dexamethasone intravitreal implant versus ranibizumab in branch retinal vein occlusion;Bandello;European Journal of Ophthalmology,2018

2. A 12-month, multicentre, randomised, parallel group study to compare the efficacy and safety of OZURDEX® versus Lucentis® in patients with branch retinal vein occlusion www.clinicaltrialsregister.eu/ctr-search/trial/2010-023900-29/results

3. Safety and efficacy study of Ozurdex® compared to Lucentis® in patients with branch retinal vein occlusion clinicaltrials.gov/ct2/show/NCT01427751

4. Ranibizumab intravitreal injections versus sham control in patients with branch retinal vein occlusion (BRVO) (Blossom) ClinicalTrials.gov/show/NCT01976338

5. Wei W To assess the efficacy and safety of individualized intravitreal ranibizumab 0.5 mg in Asian (primarily Chinese) patients with visual impairment due to macular edema secondary to branch retinal vein occlusion (BRVO) Annual Meeting of the Association for Research in Vision and Ophthalmology 2017

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3